Organization
Department of Hematology/Oncology
11 abstracts
Abstract
A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.Org: Memorial Sloan Kettering Cancer Center, Division of Gynecologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, University of Cincinnati Cancer Center, START Midwest, Grand Rapids, MI,
Abstract
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.Org: City of Hope National Medical Center, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center,
Abstract
Effect of common medications on immune checkpoint inhibitor efficacy.Org: Department of Hematology/Oncology, University of Michigan, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Veterans Affairs Ann Arbor Healthcare System,
Abstract
Second primary squamous cell cancers in the HPV de-escalation Quarterback Trials.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Otolaryngology, Head and Neck Surgery, University of Washington, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Real-world treatment patterns with lutetium-177-PSMA-617 (177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC).Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of California, Irvine, Irvine, CA, Department of Hematology/Oncology, University of California Irvine Medical Center, Hoag Family Cancer Institute and University of Southern California,
Abstract
The impact of household income on prostate cancer diagnosis, treatment, and outcomes.Org: SUNY Upstate Medical University, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, University of California Davis, Sacramento, CA, Department of Hematology/Oncology,
Abstract
Treatment pattern of early-stage premenopausal breast cancer patients with low Oncotype DX score: Single center experience.Org: Henry Ford Health System, Department of Hematology/Oncology, Detroit, MI, Henry Ford Hospital, Henry Ford Cancer Institute, Detroit, MI,
Abstract
Rates of colorectal cancer screening versus lung cancer screening: Where does the problem lie?Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer Center,
Abstract
Clinical outcomes in patients with post-chemotherapy residual non-retroperitoneal (RP) disease in non-seminomatous germ-cell tumors (NSGCT).Org: Indiana University – Purdue University Indianapolis, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Department of Hematology/Oncology,
Abstract
A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1.Org: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Indiana University Simon Cancer Center and Roudebush VAMC, Department of Hematology/Oncology, IU Simon Comprehensive Cancer Center, Melvin and Bren Simon Cancer Center, Indianapolis, IN,
Abstract
Patient perception and adherence to lung cancer screening in those who meet eligibility criteria.Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer Center,